Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal.

Poller L, Jespersen J, Ibrahim S, Pattison A; European Action on Anticoagulation.

J Thromb Haemost. 2013 Jun;11(6):1203-5. doi: 10.1111/jth.12164. No abstract available.

2.

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C.

J Thromb Haemost. 2012 Oct;10(10):1979-87. doi: 10.1111/j.1538-7836.2012.04866.x. Review.

3.

New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation.

Ahmad Y, Lip GY, Apostolakis S.

Expert Rev Cardiovasc Ther. 2012 Dec;10(12):1471-80. doi: 10.1586/erc.12.148. Review.

PMID:
23253272
4.

Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.

Dogliotti A, Paolasso E, Giugliano RP.

Clin Cardiol. 2013 Feb;36(2):61-7. doi: 10.1002/clc.22081. Epub 2013 Jan 21. Review.

5.

Underuse of oral anticoagulants in atrial fibrillation: a systematic review.

Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY.

Am J Med. 2010 Jul;123(7):638-645.e4. doi: 10.1016/j.amjmed.2009.11.025. Review.

PMID:
20609686
6.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
7.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Harris K, Mant J.

Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Review.

8.

Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.

Haft JI.

Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4. Review.

PMID:
22952215
9.

Novel oral anticoagulants in atrial fibrillation: will the benefit outweigh the cost?

Goudevenos J, Pipilis A, Vardas P.

Hellenic J Cardiol. 2012 Mar;53(2):137-41. Review. No abstract available.

10.

Stroke prevention in atrial fibrillation patients with chronic kidney disease.

Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.

Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005. Review.

PMID:
23790601
11.

Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.

Garcia DA.

Thromb Res. 2012 Jan;129(1):9-16. doi: 10.1016/j.thromres.2011.09.023. Epub 2011 Oct 21. Review.

PMID:
22018997
12.

Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.

Liew A, Eikelboom JW, O'Donnell M.

Curr Opin Cardiol. 2012 Jul;27(4):331-9. doi: 10.1097/HCO.0b013e3283540857. Review.

PMID:
22573171
13.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications.

Goette A.

Trends Cardiovasc Med. 2013 May;23(4):128-34. doi: 10.1016/j.tcm.2012.10.001. Epub 2013 Jan 11. Review.

PMID:
23313169
14.

Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.

Lang NN, Connelly DT.

J R Coll Physicians Edinb. 2013;43(2):151-8. doi: 10.4997/JRCPE.2013.213. Review.

PMID:
23734359
15.

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.

Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W.

Circulation. 2012 Nov 13;126(20):2381-91. doi: 10.1161/CIRCULATIONAHA.112.115410. Epub 2012 Oct 15. Review.

16.

Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.

Fernandez MM, von Schéele B, Hogue S, Kwong WJ.

Am J Cardiovasc Drugs. 2013 Apr;13(2):87-102. doi: 10.1007/s40256-013-0016-5. Review.

PMID:
23572283
17.

Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.

Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T.

Circ J. 2011;75(7):1539-47. Epub 2011 Jun 9. Review.

18.

New oral anticoagulants in atrial fibrillation.

Turpie AG.

Eur Heart J. 2008 Jan;29(2):155-65. Epub 2007 Dec 19. Review.

PMID:
18096568
19.

Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis.

Lega JC, Mismetti P, Cucherat M, Fassier T, Bertoletti L, Chapelle C, Laporte S.

J Thromb Haemost. 2013 Jul;11(7):1240-50. doi: 10.1111/jth.12294. Review.

20.

[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].

Selçuk H, Selçuk MT, Maden O.

Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Review. Turkish.

Supplemental Content

Support Center